Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

biOasis Technologies Ord Shs V.BTI.H

Alternate Symbol(s):  BIOAF

Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in particular biological products, across the blood-brain barrier (BBB). It is focused on both orphan drug indications, including brain cancers, and rare genetic neurodegenerative diseases and neuroinflammatory conditions. The Company is also focused on its Epidermal Growth Factor (EGF) platform for treating rare and orphan neurodegenerative and neuroinflammatory disorders. EGF is a protein that stimulates cell growth and differentiation, notably for myelin producing cells. Its development programs include xB3-001: Brain Metastases, xB3-002: Glioblastoma and xB3-007: Neurodegenerative Disease.


TSXV:BTI.H - Post by User

Post by OysterBuctoucheon Nov 23, 2018 9:53am
150 Views
Post# 29013409

BTI Share price

BTI Share priceThere has never been a better time to buy shares in Bioasis. SP is much lower then expected and could see continued tax loss pressure along with SP pressure from current cash position. The company management and plan has never been stronger. BD is real as established by Prothena deal. With what we know re BD requirements a share price purchase of $1.00 per share or above as a point in time decision was a mistake.The change of leadership as supported by prior team was a clear message that the work required had only just begun for Bioasis. Two years ago and beyond i was obviouly premature in my enthusiam for Bioasis shares. But the prior share purchase mistakes (no regrets re end state vision now) will not deter my enthusiasm for the potential now inherent in this company. Enthusiasm for both the potential BD's emerging, and the ultimate good for people and science that is becoming clearer and far closer to real.
Bullboard Posts